Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.61 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447946 | 1.00 | GPR119 (0.61) | GPR119SMARCA2SMARCA4PBRM1SETD7 | |
| SCHEMBL1447948 | 1.00 | GPR119 (0.61) | GPR119SMARCA2SMARCA4PBRM1SETD7 | |
| SCHEMBL1449149 | 0.89 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL22792019 | 0.89 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1449147 | 0.89 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL12740838 | 0.89 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL31045900 | 0.88 | GPR119 (0.61) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL12089264 | 0.87 | GPR119 (0.60) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL31713163 | 0.87 | GPR119 (0.60) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL15024213 | 0.86 | GPR119 (0.61) | GPR119SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| US-9663495-B2 | Triazolone derivatives or salts thereof and pharmaceutical composition comprising the same | YUHAN CORPORATION (KR) | 2017-05-30 | — | — | US | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2016-03-10 | — | — | US | disclosed |
| EP-2989093-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Yuhan Corporation (KR) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014175621-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2014-10-30 | — | — | WO | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GPR119, GPR88, GCGR | GPR119 1/4885SMARCA2 2802/4885SMARCA4 2458/4885 |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | GPR119 976/4885SMARCA2 4597/4885SMARCA4 4306/4885 |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | GPR119 976/4885SMARCA2 4597/4885SMARCA4 4306/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | GPR119 17/4885SMARCA2 4060/4885SMARCA4 4083/4885 |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | TNF, CD40, TNFRSF1A | GPR119 976/4885SMARCA2 4597/4885SMARCA4 4306/4885 |
| US-20110065706-A1 | Therapeutic Agents 812 | GPR119, GPR84, GPR132 | GPR119 1/4885SMARCA2 2093/4885SMARCA4 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.